If you or a loved one were diagnosed with cutaneous t-cell lymphoma (i.e., non-hodgkin’s lymphoma, mycosis fungoides or sezary syndrome) after receiving a Dupixent (dupilumab) injection, you may be entitled to recover compensation from a Dupixent CTCL lymphoma lawsuit case or settlement claim.
A team of drug injury lawyers and class action attorneys is investigating potential Dupixent lawsuit cases and settlement claims of individuals who were diagnosed with cutaneous T-cell lymphoma CTCL (i.e., non-hodgkin’s lymphoma, mycosis fungoides or sezary syndrome, etc.) after receiving Dupixent (dupilumab) injections.
Dupixent (dupilumab) is a prescription biologic (monoclonal antibody) given by subcutaneous injection (under the skin) to treat allergic diseases (e.g., atopic dermatitis, eczema, asthma and nasal polyps which result in chronic sinusitis), eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease (COPD) and other conditions.
Cutaneous T-cell lymphoma (CTCL) is a group of rare blood cancers (a form of non-Hodgkin lymphoma, including mycosis fungoides and sezary syndrome, etc.) in which T-lymphocytes (white blood cells used by the immune system to fight diseases) become cancerous (i.e., malignant) and attack the skin and other parts of the body. Unfortunately, according to research studies, patients who received Dupixent injections may be at an increased risk (perhaps as much as 4 or more times more likely) of developing cutaneous T-cell lymphoma.
Cancer victims and survivors (and their family members) are now coming forward and filing Dupixent lawsuits seeking compensation and justice for the harm and suffering they may have endured.
Dupixent T-Cell Lymphoma Lawsuit: Overview
- What Is a Dupixent (Dupilumab)?
- What Is Cutaneous T-cell Lymphoma (CTCL)?
- Has Dupixent Been Linked to Cutaneous T-cell Lymphoma (CTCL)?
- Who May Qualify For a Dupixent Lymphoma Lawsuit or Settlement?
- What Is The Depo-Provera Lawsuit About?
- Are Dupixent Users More Likely to Develop T-Cell Lymphoma?
- What Are Signs or Symptoms of Cutaneous T-cell Lymphoma?
- What Complications Can Cutaneous T-Cell Lymphoma Cause?
- Are There Medical Treatments for CTCL Lymphoma?
- What Companies May Be Sued For Dupixent Injuries?
- Can I Recover Compensation From a Dupixent Lymphoma Lawsuit?
- Is There A Time Limit To Filing a Dupixent Cancer Lawsuit?
- Request A Free Case Review From A Dupixent Injury Lawyer
Dupixent Lymphoma Lawsuit & Settlement Cases
Dupixent T-Cell Lymphoma lawsuit and settlement cases potentially being investigated include claims involving patients who, after receiving a Dupixent injection, were later diagnosed with T-cell lymphoma including:
- Cutaneous T-cell lymphoma (CTCL)
- Mycosis fungoides (MF)
- Lymphomatoid papulosis (LyP)
- Primary cutaneous anaplastic large cell lymphoma (PCALCL)
- Sézary syndrome (SS)
- Lymphoma of the skin
- Cutaneous T-cell non-Hodgkin lymphoma
- Skin T-cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
- Extranodal NK/T-cell lymphoma
- Primary cutaneous gamma/delta T-cell lymphoma (PCGDTCL)
- Peripheral T-cell lymphoma (PTCL)
- Other type of T-cell lymphoma
- Other type of lymphoma blood cancer
If you or someone you love suffered from Cutaneous T-Cell Lymphoma after receiving Dupixent injections, you may be eligible to recover compensation from a Dupixent lawsuit or settlement case.
Dupixent Cancer Injury Lawsuit Complaints
Individuals who used Dupixent for conditions like eczema (atopic dermatitis), asthma, or other indications, and were later diagnosed with CTCL or other T-cell lymphoma have filed Dupixent personal injury and wrongful death lawsuits seeking justice and financial compensation.
Plaintiffs in the Dupixent cancer injury lawsuits have alleged, among other things, that they suffered from cutaneous T-cell lymphoma after receiving Dupixent (dupilumab) injections and that defendants knew, or should have known, that Dupixent could lead to an increased risk of developing CTCL but that they did not provide an adequate warning about the risks or the need for monitoring for resultant symptoms.
The Dupixent lawsuit complaints have asserted claims for, among other things, negligence, negligent failure to warn and design defect, strict liability (failure to warn), negligent misrepresentation, fraudulent misrepresentation, breach of warranty (express and implied) and, in cases involving plaintiffs who have died, wrongful death and survival claims.
Plaintiffs in Dupixent lawsuits have sought to recover compensatory damages (such as compensation for physical pain, mental suffering, inconvenience, loss of the enjoyment of life, past and future medical expenses, loss of consortium and loss of earnings and earning capacity), punitive damages, and/or attorneys’ fees and costs, among others.
Companies That May Be Sued For Dupixent Injuries
Defendants in Dupixent lawsuits have include developers, manufacturers, sellers and/or distributors of Dupixent (dupilumab), including:
- Regeneron Pharmaceuticals, Inc.
- Sanofi-Aventis U.S. LLC
- Other potential defendants
Studies Linking Dupixent Use to Blood Cancer
Several recent scientific studies and publications have found a potential link between the use of Dupixent (dupilumab) injections and an increased risk of developing cutaneous T-cell lymphoma (CTCL).
For example, a study published in the Journal of the American Academy of Dermatology (JAAD) compared people with eczema who took dupilumab to eczema patients who didn’t take dupilumab and found that the dupilumab group had higher odds of later being diagnosed with CTCL (about 4 times higher), with most CTCL diagnoses showing up more than a year after starting the drug. See Hasan I, Parsons L, Duran S, Zinn Z. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study. J Am Acad Dermatol. 2024 Aug;91(2):255-258. doi: 10.1016/j.jaad.2024.03.039. Epub 2024 Apr 6. PMID: 38588818.
Another study published in Dermatologic Therapy compared 19,612 dupilumab users to 19,612 non-users with eczema and found that Dupilumab users had a higher relative risk of CTCL overall (~4.6x) and that about 62% of CTCL diagnoses happened within the first year after starting dupilumab. See Mandel J, Mehta J, Hafer R, Ayub M, Nusrat F, Yang H, Porcu P, Nikbakht N. Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis. Dermatol Ther. 2024 Jan;2024:9924306. doi: 10.1155/2024/9924306. Epub 2024 Aug 14. PMID: 39668908; PMCID: PMC11635927.
Types of Cutaneous T-cell Lymphomas
There are various types (or subtypes) of cutaneous T-cell lymphomas, including mycosis fungoides (MF), sézary syndrome (SS), primary cutaneous CD30⁺ lymphoproliferative disorders, primary cutaneous γ/δ T-Cell lymphoma (PCGD-TCL), primary cutaneous CD8⁺ aggressive epidermotropic cytotoxic T-cell lymphoma, primary cutaneous acral CD8⁺ T-cell lymphoma, primary cutaneous small/medium CD4⁺ T-cell lymphoproliferative disorder, subcutaneous panniculitis-like T-cell lymphoma (SPTCL), primary cutaneous peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and adult T-cell leukemia/lymphoma (ATLL):
- Mycosis Fungoides (MF) Lawsuit Cases: Mycosis fungoides is the most common subtype of CTCL, accounting for more than half of all cases. It usually progresses slowly, over years or even decades, starting as flat, scaly, and itchy patches that resemble eczema or psoriasis. As the disease advances, these patches can thicken into plaques and eventually form tumors. MF primarily affects older adults and often remains confined to the skin for a long time before spreading to lymph nodes or internal organs. Variants include folliculotropic MF (involving hair follicles), pagetoid reticulosis (localized lesions), and granulomatous slack skin, a rare form with loose, sagging skin folds.
- Sézary Syndrome (SS) Lawsuit Cases: Sézary syndrome is an aggressive leukemic form of CTCL, marked by the presence of malignant T-cells, called Sézary cells, in the blood. Patients typically develop erythroderma, a diffuse redness and scaling of nearly the entire skin surface accompanied by severe itching, hair loss, thickened palms and soles, and enlarged lymph nodes. Fatigue and systemic symptoms are also common. Because it involves both skin and blood, Sézary syndrome is considered an advanced stage of CTCL. Treatment often requires systemic therapies such as biologics, targeted monoclonal antibodies, or stem cell transplantation.
- Primary Cutaneous CD30⁺ Lymphoproliferative Disorder Cases: This CTCL group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large-cell lymphoma (pcALCL), both of which are characterized by strong expression of the CD30 marker on malignant cells. Despite their cancerous nature, these disorders often behave indolently. LyP presents as recurrent crops of red, ulcerating nodules that spontaneously heal, while pcALCL manifests as larger, persistent skin nodules or tumors that may ulcerate but rarely spread. Most cases respond well to low-dose radiation, topical therapies, or mild immunomodulatory drugs.
- Primary Cutaneous γ/δ T-Cell Lymphoma (PCGD-TCL) Cases: This is a rare and aggressive CTCL derived from gamma/delta T-cells rather than the typical alpha/beta subtype. It often affects the extremities, causing deep, ulcerated nodules or plaques involving the dermis and subcutaneous tissue. Unlike other forms, PCGD-TCL tends to resist standard therapies and has a poorer prognosis. It can also involve mucosal and visceral sites. Treatment focuses on systemic chemotherapy and clinical trials, although outcomes remain challenging.
- Primary Cutaneous CD8⁺ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma Cases: This CTCL subtype is rapidly progressive and marked by the infiltration of cytotoxic CD8⁺ T-cells into the epidermis, leading to ulcerative or necrotic lesions. Lesions may appear on the trunk, limbs, or face and often spread quickly to internal organs. Because of its aggressive nature, early systemic therapy is critical. Prognosis is typically poor, and stem cell transplantation might be considered in some cases.
- Primary Cutaneous Acral CD8⁺ T-Cell Lymphoma Cases: In contrast to the aggressive CD8⁺ variant, the acral form is usually slow-growing and indolent. It manifests as solitary or localized nodules on acral areas, such as the ears, nose, or fingers. Despite being classified as a lymphoma, this subtype rarely spreads and often responds well to local treatments, including surgical excision or radiation therapy.
- Primary Cutaneous Small/Medium CD4⁺ T-Cell Lymphoproliferative Disorder Cases: This form of CTCL presents as a solitary, slow-growing nodule or plaque, typically on the face, neck, or upper trunk. The malignant cells are small to medium in size and predominantly CD4⁺ positive. Because it behaves in an indolent fashion and rarely disseminates, it is often managed with local excision or low-dose radiation.
- Subcutaneous Panniculitis-Like T-Cell Lymphoma (SPTCL) Cases: SPTCL primarily affects the subcutaneous fat layer, producing nodules that can resemble panniculitis (inflammation of fat tissue). It often causes tender lumps on the arms, thighs, or trunk and may be accompanied by systemic symptoms like fever or weight loss. The α/β T-cell CTCL subtype is relatively indolent and responds well to steroids or immunosuppressive therapy, whereas the rarer γ/δ form behaves more aggressively. Early diagnosis and immune-modulating therapy are key to favorable outcomes.
- Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) Cases:
This is a CTCL diagnosis of exclusion, used when a CTCL does not fit other defined categories. PTCL-NOS typically presents with multiple nodules or tumors on the skin and often progresses rapidly, involving lymph nodes or internal organs. It is considered an aggressive form of CTCL and is treated with systemic chemotherapy, biologic agents, or participation in clinical trials. Prognosis varies but is generally less favorable compared to indolent CTCLs.
- Adult T-Cell Leukemia/Lymphoma (ATLL): Adult T-cell leukemia/lymphoma arises from infection with the Human T-cell Leukemia Virus Type 1 (HTLV-1). While it can affect multiple organs, the skin is commonly involved, producing patches, papules, or nodules. ATLL is seen mostly in HTLV-1 endemic regions such as Japan, the Caribbean, and parts of Africa and South America. It has several clinical variants (acute, lymphomatous, chronic, and smoldering) each with distinct severity. Treatment depends on subtype but may include antiviral therapy, chemotherapy, and newer targeted agents.
CTCL Lymphoma Signs & Symptoms
Cutaneous T-cell lymphoma (CTCL) begins in T lymphocytes (T-cells), a type of white blood cell, and primarily affects the skin. Unlike other lymphomas that develop in lymph nodes or organs, CTCL cells migrate to the skin, causing a variety of skin lesions, patches, and plaques.
Signs and symptoms of cutaneous t-cell lymphoma can include:
- Flat scaly patches on skin
- Bumps on skin
- Skin rashes that last for months
- Red, pink, gray, or brown patches
- Dry skin
- Plaques (thick, raised lesions)
- Itchy skin
- Thickened skin
- Tumors/nodules on skin
- Ulcerated tumors that break open
- Lumpy growths on the skin
- Erythroderma
- Hair loss (including brows or beard areas in men)
- Thickened palms/soles with painful cracks (palmoplantar keratoderma)
- Nail changes (ridges, yellow, rough)
- Lower eyelid turns outward (ectropion)
- Enlarged lymph nodes
- Skin infections
- Hypopigmentation (patches lighter in color)
- “Lion-like” look to the face
- Fever and chills
- Unexplained weight loss
- Fatigue
- Feeling unwell (malaise)
- Pain or tenderness
- Night sweats
- Other cutaneous t-cell lymphoma symptoms or signs
The signs and symptoms of CTCL can vary widely and often mimic other common skin conditions, like eczema, psoriasis, or chronic dermatitis, which can make diagnosis of CTCL challenging.
Procedures and tests used by dermatologists, hematologists, oncologists and other physicians to diagnose cutaneous T-cell lymphoma can include a patient history, physical examination, dermoscopy; serial skin biopsies reviewed by dermatopathology; immunohistochemistry (e.g., CD2, CD3, CD4, CD7, CD8, CD30); T-cell receptor clonality testing (PCR/NGS); peripheral-blood studies (CBC, flow cytometry, Sézary cell count); imaging for staging (CT or PET/CT); and, when indicated, lymph-node or bone-marrow biopsy, among others.
Cutaneous T-cell Lymphoma Complications
CTCL can lead to serious complications including:
- Ulcerated tumors
- Progression from patches to plaques/tumors
- Ulceration and non-healing wounds
- Secondary infections (cellulitis, sepsis, disseminated herpes/zoster)
- Erythroderma (widespread, red, scaly rash covering the body)
- Fluid/protein/electrolyte loss or imbalance
- Impaired thermoregulation (hypothermia)
- Edema
- Severe pruritus
- Immune system compromise
- Physical disfigurement
- Sleep disturbance
- Emotional distress
- Psychological distress
- Neurological complications
- Large cell transformation (LCT)
- Transformation to more aggressive, high-grade lymphoma
- Spread to other organs
- Metastasis to lymph nodes
- Metastasis organs (e.g., liver, spleen, lungs, bone marrow, etc.)
- Chronic pain
- Death
- Other cutaneous t-cell lymphoma complications
The prognosis and potential for complications are highly dependent on the type and stage of the disease at diagnosis. Patients with early-stage disease can have a very good prognosis and a near-normal life expectancy, but those with advanced disease face more significant challenges.
Cutaneous T-cell Lymphoma Treatment
Treatment for cutaneous t-cell lymphoma can include skin-directed therapies (topical corticosteroids, topical chemotherapy such as mechlorethamine, topical retinoids, phototherapy with NB-UVB or PUVA, and localized or total-skin electron-beam radiation); systemic agents for refractory/advanced disease (bexarotene, interferon-α, low-dose methotrexate, HDAC inhibitors like vorinostat or romidepsin); targeted/immune therapies (brentuximab vedotin for CD30⁺ disease, mogamulizumab, checkpoint inhibitors in select cases); and, in some patients, allogeneic hematopoietic stem-cell transplantation.
Recover Compensation For Lymphoma Injuries
When an injury (such as cutaneous t-cell lymphoma) is caused by someone else’s negligence, victims may be entitled to financial compensation. Plaintiffs who bring Dupixent lawsuits may be able to recover money damages for harms and losses suffered as a result of their being diagnosed with CTCL, including compensation for:
- Medical expenses (past and future): Cancer victims may be entitled to compensation for all reasonable and necessary medical costs, both past and future, incurred as a result of their lymphoma diagnosis, including dermatology/oncology visits; skin biopsies and pathology; staging and monitoring (blood tests for Sézary cells, T-cell receptor studies, flow cytometry, and PET/CT or CT scans), medications, skin-directed therapies (such as phototherapy and total skin electron beam therapy) and hospitalizations for infections, flares, or complications. In some cases, recoverable costs may encompass extracorporeal photopheresis, infusion services, radiation or chemotherapy, stem-cell transplant evaluation, wound-care supplies, home-health nursing, pain management, and psychosocial support. Rehabilitation for fatigue or neuropathy, transportation to specialty centers, caregiver respite, and insurance expenses (premiums, copays, deductibles) might be included. A comprehensive oncology life-care plan may be used to project future CTCL lymphoma needs and ensure the full scope of long-term surveillance and supportive care is financially accounted for.
- Lost wages/income (past and future)/Loss of earning capacity: If lymphoma complications or treatments cause a victim to miss work, they may recover compensation for all income lost during their recovery period (e.g., lost wages, lost bonuses, commissions, and other benefits). In cases of more severe injury, where the victim cannot return to their previous occupation or work at all, compensation may also include projected future income losses. If victims experience long-term or permanent reduction in their ability to earn income that prevents a return to the same job, full-time hours, or reliable attendance, they may recover for loss of earning capacity (which considers the person’s age, disease stage and expected course, profession, skills, and likely career trajectory had the lymphoma not occurred, as well as the impact of necessary accommodations and time-intensive ongoing care. Some jobs (manual labor, outdoor work, or public-facing positions) may be especially difficult to return to due to mobility limits, infection risk, or visible skin disease.
- Pain and suffering: Lymphoma victims may be entitled to compensation for the physical pain, discomfort and suffering resulting from the cancer and related treatments. Unlike medical bills or lost income, pain and suffering damages are non-economic damages, meaning they don’t have a clear dollar amount and can vary case by case. Compensation may reflect intense and relentless itching and burning, painful or ulcerated skin lesions, infections, sleep disruption, photosensitivity from therapies, fatigue, and treatment side effects.
- Mental anguish/emotional distress: Living with a chronic cancer (and in particular one that affects appearance) can lead to anxiety, depression, social withdrawal, and fear of progression or relapse. Compensation for such psychological harm may be recoverable.
- Loss of enjoyment / quality of life: Plaintiffs with cutaneous t-cell lymphoma may no longer comfortably participate in activities or hobbies they once loved (e.g., swimming, outdoor sports, travel) due to skin pain, sun/heat sensitivity, bandaging, or self-consciousness about visible lesions. Compensation for loss of enjoyment of life aims to account for this deeply personal impact.
- Scarring/disfigurement: Persistent plaques, tumors, ulcers, and treatments can leave permanent discoloration, scarring, or changes to hair, nails, or eyelids (e.g., ectropion).
- Home-care needs: Some CTCL patients may require help with daily activities during flares or erythroderma (bathing, dressing, dressing changes, medication administration), or periodic skilled nursing for complex wound care, which may be compensable as damages.
- Out-of-pocket and incidental costs: Travel and lodging for specialty cancer centers, parking, copays/deductibles, over-the-counter creams and emollients, special clothing/bedding for sensitive skin, and home phototherapy equipment (when prescribed) may also be compensable.
- Loss of consortium: In some cases, spouses/partners may seek damages for the impact on companionship, intimacy, and household support caused by CTCL and its treatment.
- Wrongful death damages: Certain family and loved ones of individuals who may have died as a result of their lymphoma diagnosis may be able to recover financial compensation from a Dupixent wrongful death lawsuit or settlement claim. Dupixent wrongful death lawsuit damages might include, among other things, pecuniary losses suffered by a surviving spouse or next of kin of the deceased family member, such as past and future loss of money, income, benefits, goods, services, or loss of society (i.e., love, affection, care, attention, companionship, comfort, guidance, and protection).
- Other possible monetary damages: Other unique financial harms or complications tied to CTCL (e.g., prolonged hospitalizations for sepsis, vision issues from eyelid involvement, etc.) might be recoverable in a t-cell lymphoma lawsuit, depending on the particular circumstances of a case.
Time Is Limited To File A Dupixent Lawsuit
Deadlines called statutes of limitation and statutes of repose may limit the time that individuals have to file a Dupixent lawsuit to try to recover compensation for injuries they claim to have suffered (e.g., cutaneous t-cell lymphoma and related complications) after taking Dupixent.
This means that if a Dupixent lawsuit claim is not filed before the applicable deadline or limitations period, the injured party may be barred from ever pursuing litigation or taking legal action regarding their Dupixent injury claim. That is why it is important to connect with a Dupixent injury lawyer or attorney as soon as possible.
Connect With A Dupixent Injury Attorney
Navigating the aftermath of a cutaneous T-cell lymphoma diagnosis can be overwhelming for victims and their families, especially when the injury could be linked to a medication (i.e., Dupixent) that they were prescribed. A Dupixent injury attorney can help evaluate your situation, explain your options, and protect your legal rights while you focus on treatment, recovery and healing.
Dupixent injury cases are handled on a contingency fee basis, meaning clients pay no attorney’s fees unless compensation is recovered by their lawyers (in which case, the attorneys get paid a percentage of the amount of any settlement or award recovered). This makes legal representation accessible to cancer injury victims, regardless of their financial circumstances.
If you or a loved one have suffered from cutaneous t-cell lymphoma (CTCL), mycosis fungoides, sezary syndrome or other non-Hodgkin lymphoma after receiving Dupixent injections, you may be entitled to compensation from a Dupixent lawsuit case or settlement claim. Contact a drug injury lawyer to request a free case review.
*If you or a loved one are experiencing health issues, side effects or complications after taking a prescription drug or medication, we urge you to promptly consult with your doctor or physician for an evaluation.
**The listing of a company (e.g., Regeneron Pharmaceuticals, Inc. and/or Sanofi-Aventis U.S. LLC) or product (e.g., Dupixent) is not meant to state or imply that the company acted illegally or improperly or that the product is unsafe or defective; rather only that an investigation may be, is or was being conducted to determine whether legal rights have been violated.
***The use of any trademarks, tradenames or service marks is solely for product identification and/or informational purposes.
Fill out the form to request a free attorney review.